RCEL vs. UTMD, SGHT, ANGO, INO, ARAY, LUNG, CERS, PROF, DRTS, and LYRA
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include Utah Medical Products (UTMD), Sight Sciences (SGHT), AngioDynamics (ANGO), Inovio Pharmaceuticals (INO), Accuray (ARAY), Pulmonx (LUNG), Cerus (CERS), Profound Medical (PROF), Alpha Tau Medical (DRTS), and Lyra Therapeutics (LYRA). These companies are all part of the "surgical & medical instruments" industry.
Utah Medical Products (NASDAQ:UTMD) and AVITA Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
Utah Medical Products received 80 more outperform votes than AVITA Medical when rated by MarketBeat users. However, 68.57% of users gave AVITA Medical an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.
AVITA Medical has a consensus target price of $27.80, indicating a potential upside of 209.58%. Given Utah Medical Products' higher probable upside, analysts plainly believe AVITA Medical is more favorable than Utah Medical Products.
69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 27.7% of AVITA Medical shares are held by institutional investors. 6.5% of Utah Medical Products shares are held by insiders. Comparatively, 2.1% of AVITA Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Utah Medical Products has higher revenue and earnings than AVITA Medical. AVITA Medical is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
Utah Medical Products has a net margin of 33.12% compared to Utah Medical Products' net margin of -70.56%. AVITA Medical's return on equity of 13.53% beat Utah Medical Products' return on equity.
In the previous week, AVITA Medical had 2 more articles in the media than Utah Medical Products. MarketBeat recorded 3 mentions for AVITA Medical and 1 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 0.00 beat AVITA Medical's score of -0.27 indicating that AVITA Medical is being referred to more favorably in the news media.
Utah Medical Products has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, AVITA Medical has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
Summary
Utah Medical Products beats AVITA Medical on 11 of the 17 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
